文献速递肿瘤 PET/CT神经核医学

[68Ga]Ga-NOTA-(TMVP1)2同源二聚体肽放射性示踪剂用于宫颈癌患者VEGFR-3成像

Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-27

本研究开发了靶向血管内皮生长因子受体3(VEGFR-3)的同源二聚体肽探针[68Ga]Ga-NOTA-(TMVP1)2,在C33A宫颈癌皮下移植瘤小鼠中行microPET显像与生物分布研究,并在5名健康志愿者和8例宫颈癌患者中行全身PET/CT显像。结果显示该探针合成便利、亲和力高、主要经肾脏排泄,在宫颈癌患者中耐受良好,多数[18F]-FDG识别病灶(18/22,81.8%)呈中至高信号,作者认为可评估宫颈癌患者VEGFR-3表达并值得进一步临床研究。

要点

  • 同源二聚体TMVP1对VEGFR-3的亲和力高于单体TMVP1。
  • C33A荷瘤小鼠中肿瘤摄取为2.32±0.10% ID/g,未标记肽预处理后降至0.58±0.01% ID/g。
  • 宫颈癌患者中18/22(81.8%)的[18F]-FDG识别病灶在[68Ga]Ga-NOTA-(TMVP1)2上呈中至高信号。

核心结论

  • [68Ga]Ga-NOTA-(TMVP1)2合成便利、比活度高、肿瘤摄取高,可用于评估宫颈癌患者的VEGFR-3,并值得进一步临床研究。

研究设计与样本

  • 本研究构建了经PEG4和Gly3连接子偶联NOTA并用68Ga标记的TMVP1同源二聚体[68Ga]Ga-NOTA-(TMVP1)2,行分子对接、亲和力与细胞结合实验。
  • 在C33A宫颈癌皮下移植瘤小鼠中行microPET显像与生物分布研究。
  • 5名健康志愿者和8例宫颈癌患者在静脉注射[68Ga]Ga-NOTA-(TMVP1)2后30-45分钟行全身PET/CT采集。
  • 试验注册号ChiCTR-DOD-17012458,2017年8月23日回顾性注册。

主要发现

  • 分子对接与细胞实验均显示同源二聚体TMVP1对VEGFR-3的亲和力高于单体TMVP1。
  • [68Ga]Ga-NOTA-(TMVP1)2主要经肾脏排泄,部分经肝脏排泄。
  • C33A荷瘤小鼠中[68Ga]Ga-NOTA-(TMVP1)2特异性聚集于肿瘤,摄取为2.32±0.10% ID/g;未标记肽NOTA-(TMVP1)2预处理后肿瘤摄取降至0.58±0.01% ID/g。
  • 所有健康志愿者和入组患者中[68Ga]Ga-NOTA-(TMVP1)2均安全,未观察到副作用或过敏反应。
  • 宫颈癌患者中多数[18F]-FDG识别病灶(18/22,81.8%)在[68Ga]Ga-NOTA-(TMVP1)2上呈中至高信号,SUVmax为2.32±0.77,SUVmean为1.61±0.48。

局限性

  • 原文在结论中提出该探针值得进一步临床研究。
  • 试验为回顾性注册(2017年8月23日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vascular endothelial growth factor receptor 3 (VEGFR-3) plays a critical role in tumor lymphangiogenesis and metastasis, holding promise as a promising therapeutic target for solid tumors. TMVP1 (LARGR) is a 5-amino acid peptide previously identified in our laboratory from bacterial peptide display system that specifically targets VEGFR-3. Radiolabeled TMVP1 can be used for non-invasive imaging of VEGFR-3 expressing tumors. Homodimeric peptides have better targeting ability than monomeric peptides, and it is worth exploring whether homodimers of TMVP1 ((TMVP1)2) can achieve better imaging effects. This study aimed to explore the peptide properties and tumor assessment value of [68Ga]Ga-labeled (TMVP1)2. METHODS: In this study, we developed a TMVP1 homodimer that was conjugated with 1,4,7-triazacyclononane-N, N', N″-triacetic acid (NOTA) via tetraethyleneglycol (PEG4) and triglyicine (Gly3) spacer, and labeled with 68Ga, to construct [68Ga]Ga-NOTA-(TMVP1)2. Binding of VEGFR-3 by TMVP1 and (TMVP1)2, respectively, was modeled by molecular docking. The affinity of [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 and its ability to bind to cells were evaluated. MicroPET imaging and biodistribution studies of [68Ga]Ga-NOTA-(TMVP1)2 were performed in subcutaneous C33A cervical cancer xenografts. Five healthy volunteers and eight patients with cervical cancer underwent whole-body PET/CT acquisition 30-45 min after intravenous injection of [68Ga]Ga-NOTA-(TMVP1)2. RESULTS: Both molecular docking and cellular experiments showed that homodimeric TMVP1 had a higher affinity for VEGFR-3 than monomeric TMVP1. [68Ga]Ga-NOTA-(TMVP1)2 was excreted mainly through the renal route and partly through the liver route. In mice bearing C33A xenografts, [68Ga]Ga-NOTA-(TMVP1)2 specifically localized in the tumor (2.32 ± 0.10% ID/g). Pretreatment of C33A xenograft mice with the unlabeled peptide NOTA-(TMVP1)2 reduced the enrichment of [68Ga]Ga-NOTA-(TMVP1)2 in tumors (0.58 ± 0.01% ID/g). [68Ga]Ga-NOTA-(TMVP1)2 proved to be safe in all healthy volunteers and recruited patients, with no side effects or allergies noted. In cervical cancer patients, a majority of the [18F]-FDG identified lesions (18/22, 81.8%) showed moderate to high signal intensity on [68Ga]Ga-NOTA-(TMVP1)2. SUVmax and SUVmean were 2.32 ± 0.77 and 1.61 ± 0.48, respectively. With normal muscle (gluteus maximus) as background, tumor-to-background ratios were 3.49 ± 1.32 and 3.95 ± 1.64 based on SUVmax and SUVmean, respectively. CONCLUSION: The favorable characterizations of [68Ga]Ga-NOTA-(TMVP1)2 such as convenient synthesis, high specific activity, and high tumor uptake enable the evaluation of VEGFR-3 in cervical cancer patients and warrant further clinical studies. TRIAL REGISTRATION: ChiCTR-DOD-17012458. Registered August 23, 2017 (retrospectively registered).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen X, Zhang Z, Wang L, et al. Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients. Eur J Nucl Med Mol Imaging. 2024. PMID: 38411667. doi:10.1007/s00259-024-06661-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。